Central nervous system (CNS) leukemia after imatinib mesylate therapy for chronic myelogenous leukemia (CML)

被引：0
|
作者：
Solh, M. M.
Kantarjian, H.
O'Brien, S.
Giles, F.
Faderl, S.
Garcia-Manero, G.
Rios, M.
Shan, J.
Cortes, J.
Ravandi-Kashani, F.
机构：
[1] Wayne State Univ, Detroit Med Ctr, Detroit, MI USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7042
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Effective treatment of basophilic leukemia of the central nervous system in a CML patient with the combination of imatinib mesylate and valproic acid.
    Nahajevszky, S
    Magocsi, M
    Mikala, G
    Andrikovics, H
    Adam, E
    Masszi, T
    BLOOD, 2005, 106 (11) : 301B - 302B
  • [32] Central nervous system is a sanctuary site for chronic myelogenous leukaemia treated with imatinib mesylate
    Isobe, Y.
    Sugimoto, K.
    Masuda, A.
    Hamano, Y.
    Oshimi, K.
    INTERNAL MEDICINE JOURNAL, 2009, 39 (06) : 408 - 411
  • [33] Interstitial lung disease associated with imatinib (Gleevec) therapy for chronic myelogenous leukemia (CML).
    Donna, E
    Ahn, YS
    Huang, HS
    Horstman, LL
    Jimenez, JJ
    Jy, WC
    BLOOD, 2002, 100 (11) : 327B - 327B
  • [34] IMATINIB MESYLATE INDUCED HEPATOTOXICITY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML)
    Milosevic, V.
    Bogdanovic, A.
    Djordjevic, V.
    Fekete, M. Dencic
    Mihaljevic, B.
    Gotic, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 545 - 546
  • [35] Effect of Imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells
    Holtz, MS
    Bhatia, R
    LEUKEMIA & LYMPHOMA, 2004, 45 (02) : 237 - 245
  • [36] Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
    Kantarjian, H
    Sawyers, C
    Hochhaus, A
    Guilhot, F
    Schiffer, C
    Gambacorti-Passerini, C
    Niederwieser, D
    Resta, D
    Capdeville, R
    Zoellner, U
    Talpaz, M
    Druker, B
    NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09): : 645 - 652
  • [37] Severe periorbital edema secondary to imatinib mesylate for chronic myelogenous leukemia
    Larson, Jill S. Melicher
    Bergstrom, Lance K.
    Cameron, J. Douglas
    Erickson, Lori A.
    Grimm, Terrence E.
    ARCHIVES OF OPHTHALMOLOGY, 2007, 125 (07) : 985 - 986
  • [38] Imatinib mesylate in combination with other chemotherapeutic agents for chronic myelogenous leukemia
    Tauchi, T
    Ohyashiki, K
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2004, 79 (05) : 434 - 440
  • [39] Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
    Hwang, Yu-Yan
    Tse, Eric
    So, Jason C. C.
    Wan, Thomas S. K.
    Kwong, Yok-Lam
    AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (05) : 302 - 305
  • [40] Survival advantage of imatinib mesylate in newly diagnosed chronic myelogenous leukemia
    Nature Clinical Practice Oncology, 2006, 3 (12): : 646 - 647
12345